J. H. Lin, Drug-drug interaction mediated by inhibition and induction of P-glycoprotein, Adv. Drug Delivery Rev, vol.55, pp.53-81, 2003.

M. R. Lugo and F. J. Sharom, Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site, Biochemistry, vol.44, pp.643-655, 2005.

C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton et al., Communication between multiple drug binding sites on P-glycoprotein, Mol. Pharmacol, vol.58, pp.624-632, 2000.

F. Milletti, L. Storchi, G. Sforna, and G. Cruciani, New and Original pKa Prediction Method Using Grid Molecular Interaction Fields, J. Chem. Inf. Model, vol.47, pp.2172-2181, 2007.

F. Montanari and G. F. Ecker, Prediction of drug-ABC-transporter interaction-Recent advances and future challenges, Adv. Drug Delivery Rev, vol.86, pp.17-26, 2015.

R. S. Obach, R. L. Walsky, K. Venkatakrishnan, E. A. Gaman, J. B. Houston et al., The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions, J. Pharmacol. Exp. Ther, vol.316, pp.336-348, 2006.

I. J. Onakpoya, C. J. Heneghan, and J. K. Aronson, Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature, BMC medicine, vol.14, p.10, 2016.

I. K. Pajeva, M. Hanl, and M. Wiese, Protein Contacts and Ligand Binding in the Inward-Facing Model of Human P-Glycoprotein, ChemMedChem, vol.8, pp.748-762, 2013.

C. Pauli-magnus, S. Rekersbrink, U. Klotz, and M. F. Fromm, Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein, Naunyn-Schmiedeberg's Arch. Pharmacol, vol.364, pp.551-557, 2001.

J. W. Polli, S. A. Wring, J. E. Humphreys, L. Huang, J. B. Morgan et al., Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Ther, vol.299, pp.620-628, 2001.

J. Rautio, J. E. Humphreys, L. O. Webster, A. Balakrishnan, J. P. Keogh et al., In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates, Drug Metab. Dispos, vol.34, pp.786-792, 2006.

A. D. Rodrigues, Drug-drug interactions, 2008.

D. Schuster, C. Laggner, and T. Langer, Why drugs fail-a study on side effects in new chemical entities, Curr. Pharm, 2005.

. Des, , vol.11, pp.3545-3559

A. B. Shapiro and V. Ling, Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem, vol.250, pp.130-137, 1997.

Y. Sun, R. J. Kathawala, S. Singh, K. Zheng, T. T. Talele et al., Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance, Anti-Cancer Drugs, vol.23, pp.865-873, 2012.

A. C-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t,

G. Szakacs, A. Varadi, C. Özvegy-laczka, and B. Sarkadi, The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox), Drug discovery today, vol.13, pp.379-393, 2008.

M. V. Varma, K. S. Pang, N. Isoherranen, and P. Zhao, Dealing with the complex drug-drug interactions: towards mechanistic models, Biopharm. Drug Dispos, vol.36, pp.71-92, 2015.

J. Weiss, S. G. Dormann, M. Martin-facklam, C. J. Kerpen, N. Ketabi-kiyanvash et al., Inhibition of P-glycoprotein by newer antidepressants, J. Pharmacol. Exp. Ther, vol.305, pp.197-204, 2003.

M. Zeino, M. E. Saeed, O. Kadioglu, and T. Efferth, The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter, Invest. New Drugs, vol.32, pp.618-625, 2014.

L. Zhang, Y. D. Zhang, P. Zhao, and S. Huang, Predicting drug-drug interactions: an FDA perspective, The AAPS journal, vol.11, pp.300-306, 2009.

J. K. Zolnerciks, C. L. Booth-genthe, A. Gupta, J. Harris, and J. D. Unadkat, Substrate-and species-dependent inhibition of p-glycoprotein-mediated transport: Implications for predicting in vivo drug interactions, J. Pharm. Sci, vol.100, pp.3055-3061, 2011.